| Literature DB >> 27727291 |
Salvador Damián-Zamacona1, Paola Toledo-Ibelles1, Mabel Z Ibarra-Abundis2, Laura Uribe-Figueroa2, Enrique Hernández-Lemus2, Karla Paola Macedo-Alcibia2, Blanca Delgado-Coello1, Jaime Mas-Oliva1, Juan Pablo Reyes-Grajeda2.
Abstract
BACKGROUND: Although nowadays it is well known that the human transcriptome can importantly vary according to external or environmental condition, the reflection of this concept when studying oxidative stress and its direct relationship with gene expression profiling during the process of atherogenesis has not been thoroughly achieved.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27727291 PMCID: PMC5058556 DOI: 10.1371/journal.pone.0163924
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Top molecular and cellular functions significantly affected by the internalization of nLDL or oxLDL carried out at different times correlated with the top canonical pathways involved.
| TX | Molecular and cellular functions | Enrichment (P value) | Top canonical pathways | p-value (Molecule counts) |
|---|---|---|---|---|
| nLDL 1h | Cell cycle | 2.81E-05–4.57E-02 (19) | CNTF signaling | 8.03E-05 (5) |
| DNA replication,recombination and repair | 3.38E-04–4.21E-02 (11) | EGF signaling | 1.97E-03 (4) | |
| Gene expression | 3.99E-04–2.13E-02 (5) | VEGF signaling | 9.31E-04 (4) | |
| Cellular growth and proliferation | 4.93E-04–4.83E-02 (19) | Thrombopoietin signaling | 1.38E-03 (5) | |
| Cellular assembly and organization | 1.11E-03–4.21E-02 (20) | IL-2 signaling | 1.69E-03 (4) | |
| nLDL 5h | Cell cycle | 2.10E-06–4.89E-02 (32) | PPARα/RXRα | 8.83E-05 (13) |
| Cellular development | 1.98E-04–4.45E-02 (28) | Activation TGF-β signaling | 1.34E-04 (9) | |
| Cellular movement | 6.91E-04–4.35E-02 (19) | Molecular mechanisms of cancer | 2.58E-04 (20) | |
| Cell-To-Cell signaling and interaction | 9.18E-04–2.63E-02 (10) | Regulation of IL-2 expression in activated and anergic T | 7.06E-04 (8) | |
| Cellular growth and proliferation | 1.34E-03–4.76E-02 (34) | Lymphocytes, VEGF signaling | 9.2E-04 (8) | |
| nLDL 24h | Cellular movement | 7.09E-05–4.16E-02 (8) | LXR/RXR activation | 2.33E-03 (4) |
| Gene expression | 9.24E-05–4.97E-02 (21) | Polyamine regulation in colon cancer | 6.93E-03 (2) | |
| Cell-To-Cell signaling and interaction | 1.37E-04–5.00E-02 (21) | Oncostatin M signaling | 2.81E-02 (2) | |
| Cell cycle | 1.45E-04–4.97E-02 (14) | Germ Cell-Sertoli cell junction signaling | 3.02E-02 (4) | |
| Cellular growth and proliferation | 2.31E-04–4.97E-02 (31) | Production of nitric oxide and reactive oxygen species in macrophages | 23E-02 (4) | |
| oxLDL 1h | Cellular growth and proliferation | 5.69E-07–4.74E-02 (34) | Corticotropin releasing hormone signaling | 2.68E-03 (5) |
| Cell cycle | 1.00E-06–4.74E-02 (15) | Antiproliferative role of somatostatin receptor | 2.82E-03 (4) | |
| Cellular assembly and organization | 9.25E-05–4.74E-02 (11) | Tight junction signaling | 2.89E-03 (7) | |
| Cellular movement | 1.53E-04–3.81E-02 (22) | Endothelin-1 signaling | 4.14E-03 (6) | |
| DNA replication,recombination and repair | 2.76E-04–4.74E-02 (14) | Nitric oxide signaling in the cardiovascular system | 4.88E-03 (4) | |
| oxLDL 5h | Cell cycle | 2.96E-06–4.46E-02 (32) | Endothelin-1 signaling | 1.96E-03 (10) |
| Cellular growth and proliferation | 1.42E-05–4.22E-02 (57) | ILK signaling | 2.36E-03 (10) | |
| Cellular movement | 1.20E-04–4.66E-02 (48) | Relaxin signaling | 3.01E-03 (8) | |
| DNA replication, recombination and repair | 1.24E-04–4.46E-02 (11) | Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis | 3.11E-03 (14) | |
| Cellular assembly and organization | 4.52E-04–4.22E-02 (18) | Mitotic roles of Polo-like kinase | 5.27E-03 (5) | |
| oxLDL 24h | Cell Cycle | 1.04E-04–3.81E-02 (56) | RhoA signaling | 1.22E-02 (9) |
| Cellular movement | 1.55E-04–3.81E-02 (56) | Mitotic roles of Polo-like kinase | 1.49E-02 (6) | |
| Cellular development | 5.43E-04–3.81E-02 (58) | Germ cell-Sertoli cell Junction signaling | 1.71E-02 (12) | |
| Cellular growth and proliferation | 6.93E-04–3.81E-02 (92) | Polyamine regulation in colon cancer | 1.77E-02 (3) | |
| Gene Expression | 8.45E-04–3.81E-02 (26) | Leukocyte extravasation signaling | 2.59E-02 (12) |
Both lists were based on the Ingenuity Pathway Analysis (IPA).
*P values correspond to a range between the highest and the lowest significant result.
Fig 1Hierarchical cluster analysis of the differentially expressed genes with more than 2-fold changed expression in one out of six groups (nLDL 1h, nLDL 5h, nLDL 24h, oxLDL 1h, oxLDL 5h and oxLDL 24h) compared to parental hVSMC cells.
The dendrogram on the left indicates correlation between gene expression profiles. The columns in the middle show the normalized expression of each gene in pseudocolor scale (key in the upper).
hVSMC showing differential time dependent (1 to 24h) gene expression when exposed to nLDL or oxLDL.
| Gene symbol | Gene description | Fold change | Location | |||||
|---|---|---|---|---|---|---|---|---|
| nLDL 1h | nLDL5h | nLDL 24h | oxLDL 1h | oxLDL 5h | oxLDL 24h | |||
| FOS | FBJ Murine Osteosarcoma Viral Oncogene Homolog | 1.154 | 1.714 | 1.346 | 1.119 | 1.176 | Nuclear, transcription factor | |
| EGR1 | Early Growth Response 1 | -1.667 | -1.118 | -1.044 | -1.814 | -1.638 | Nuclear, transcriptional regulator | |
| DUSP1 | Dual SpecificityPhosphatase 1 | 1.359 | -1.055 | -1.055 | -1.009 | Nuclear | ||
| MIR21 | MicroRNA 21 | 1.254 | -1.475 | 1.326 | 1.903 | Cytoplasm | ||
| MMP16 | Matrix Metallopeptidase 16 | 1.779 | 1.044 | 1.264 | 1.856 | Cell membrane, Extracellular side | ||
| PHF3 | PHD finger protein 3 | -1.458 | 1.788 | -1.088 | Nucleus | |||
| EXOC5 | Exocyst Complex Component 5 | -1.203 | -1.086 | 1.153 | -1.025 | -1.034 | Cytoplasm | |
| RB1CC1 | RB1-Inducible Coiled-Coil 1 | -1.888 | 1.863 | 1.048 | 1.824 | Nucleus, Cytoplasm, Cytosol | ||
| DST | Dystonin | 1.355 | -1.029 | 1.722 | Cytoplasm, cytoskeleton | |||
| PPP1R10 | Protein Phosphatase 1, Regulatory Subunit 10 | 1.032 | -1.080 | 1.579 | Nucleus | |||
| HIST1H2BF | Histone Cluster 1, H2bf | 1.365 | 1.009 | 1.079 | -1.114 | -1.102 | Nucleus, Chromosome | |
| DLX5 | Distal-Less Homeobox 5 | 1.273 | 2.070 | 1.054 | 1.887 | Nucleus (by similarity) Membrane; Multi-pass membrane protein | ||
| SLC7A11 | Solute Carrier Family 7 Member 11 | 1.872 | 1.040 | 1.572 | Plasma membrane | |||
| TIPARP | TCDD-Inducible Poly (ADP-Ribose) Polymerase | -1.186 | -1.521 | Nucleus | ||||
| ROCK2 | Rho-Associated, Coiled-Coil Containing Protein Kinase 2 | 1.388 | 1.053 | 1.177 | 1.910 | Cytoplasm, cytoskeleton, Cell membrane, nucleus | ||
| GLS | Glutaminase | -1.155 | 1.018 | -1.289 | 1.024 | |||
| DDIT3 | DNA-Damage-Inducible Transcript 3 | 1.090 | 1.384 | -1.277 | Cytoplasm, Nucleus | |||
| ABCA1 | ATP-Binding Cassette, Sub-Family A (ABC1), Member 1 | -1.346 | -1.550 | -1.195 | 1.909 | Membrane | ||
| OGN | Osteoglycin | -1.741 | -1.166 | -1.026 | 1.354 | Secreted, extracellular space, ECM | ||
| MYC | V-MycMyelocytomatosis Viral Oncogene hom | 1.044 | 1.620 | 1.037 | Nucleus | |||
| HSD17B6 | Hydroxysteroid (17-Beta) Dehydrogenase 6 | 1.042 | -1.293 | -1.068 | Microsome membrane, Lumenal side, Early endosome membrane | |||
| INSIG1 | Insulin Induced Gene 1 | -1.677 | -1.381 | 1.520 | 1.487 | -1.456 | Endoplasmic reticulum membrane | |
| LDLR | Low Density Lipoprotein Receptor | 1.124 | -1.100 | -1.017 | 1.387 | -1.375 | Cell membrane | |
| KIAA1199 | KIAA1199: Colon Cancer Secreted Protein 1 | -1.115 | -1.318 | -1.152 | -1.368 | Cytoplasm | ||
| ID3 | Inhibitor of DNA Binding 3, Dominant Negative HLH-P | 1.078 | -1.227 | Nucleus | ||||
| IL1R1 | Interleukin 1 Receptor, Type I | -1.434 | -1.144 | -1.660 | -1.849 | Membrane | ||
| CALCRL | Calcitonin Receptor-Like | -1.459 | -1.361 | Cell membrane | ||||
| MYOZ2 | Myozenin 2 | 1.001 | -1.134 | 1.067 | Cytoplasm, myofibril, sarcomere | |||
| GUCY1A2 | GuanylateCyclase 1, Soluble, Alpha 2 | -1.037 | -1.101 | 1.499 | Cytoplasm | |||
| TNFSF4 | TNF (Ligand) Superfamily, Member 4 | -1.195 | 1.032 | 1.757 | Secreted | |||
| TFPI2 | Tissue Factor Pathway Inhibitor 2 | -1.382 | -1.329 | 1.109 | Nucleus, Cytoplasm | |||
| KIAA0101 | PCNA-binding protein | -1.385 | -1.059 | -1.438 | Nucleus, cytoplasm, perinuclear region | |||
| PTGS1 | Prostaglandin-Endoperoxide Synthase 1 | 1.045 | 1.052 | -1.131 | Endoplasmic reticulum and Microsome membrane | |||
| BEX1 | Brain Expressed, X-Linked 1 | 1.107 | -1.051 | -1.126 | Nucleus, Cytoplasm | |||
| ACTG2 | Actin, Gamma 2, Smooth Muscle, Enteric | 1.261 | 1.274 | -2.802 | Cytoplasm | |||
| IL33 | Interleukin 33 | -1.110 | 1.142 | 1.467 | Nucleus, cytoplasmic vesicle | |||
| PPM1K | Protein Phosphatase, Mg2+/Mn2+ Dependent, 1K | -1.409 | -1.579 | 1.441 | 1.005 | Mitochondrion matrix | ||
| RASSF9 | Ras Association (RalGDS/AF-6) Domain Family (N-terminal) Member 9 | -1.008 | 1.462 | -1.085 | Accumulates on perinuclear endosomes | |||
| TEK | Tyrosine Kinase, Endothelial | -1.268 | -1.047 | 1.072 | Cell membrane, cytoplasm, secreted | |||
| CMAHP | CytidineMonophospho-N-Acetylneuraminic Acid Hydroxylase, Pseudogene | -1.512 | -1.242 | 2.440 | 1.285 | 1.917 | Cytoplasm (infered) | |
| OCLN | Occludin | -1.030 | 1.006 | 1.412 | -1.181 | Membrane; Multi-pass membrane protein | ||
* Genes showing a significant expression change are indicated with bold numbers (P<0.05, FC>2.0).
TNF, Tumor Necrosis Factor; HLH-P, Helix-Loop-Helix Protein; ECM, extracellular matrix
Fig 2Hierarchical cluster analysis of several receptors and their expression when the six experimental conditions used (nLDL 1h, nLDL 5h, nLDL 24h, oxLDL 1h, oxLDL 5h and oxLDL 24h) are compared to parental hVSMC cells.
Fig 3Validation of microarray results by quantitative RT-PCR (A) Gene expression of ABCA1, SPP1, ZNF292,IL33, CALCRL, PRC1, KIF4A and C3 determined by quantitative real-time RT-PCR. Bars represent means ± SD (n = 3). Relative gene expression levels, normalized to GAPDH expression. Values superscribed by asterisks (*) are significantly different from nLDL and oxLDL groups (B) Heatmap Expression profile (microarray data).
Fig 4Summary of main changes observed in gene expression and functions of hVSMC as a result of exposition to oxLDLs.
Genes found over- or under-expressed in comparison to a control condition are shown (red and green respectively), and the predicted activation or inhibition in orange and blue.
Fig 5Internalization Assays and lipid peroxidation in VSMC cells.
White boxes corresponding at internalization in VSMC cells of 7.5 μg/mL of nLDLs or oxLDLs DiI label for 0 (Control), 1, 5, and 24 h under medium minimal culture conditions. The magnitude of internalization shown on the left side in the y-axis as relative fluorescence units (RFU) at 530/590 nm (excitation/emission). The blue squares correspond to the level of peroxidation of media supernatant after the same conditions. The lipid peroxidation level is shown in the y-axis on the right side expressed as [μM] of malondialdehyde.